Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

[1]  B. Zinman,et al.  Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis , 2014, The Lancet.

[2]  M. Songini,et al.  High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). , 2014, European journal of endocrinology.

[3]  F. Tinahones,et al.  Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. , 2014, Journal of diabetes and its complications.

[4]  Deepak L. Bhatt,et al.  Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial , 2014, Circulation.

[5]  B. Hoogwerf,et al.  Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes , 2014, Diabetes Care.

[6]  W. Lane,et al.  The effect of addition of liraglutide to high‐dose intensive insulin therapy: a randomized prospective trial , 2014, Diabetes, obesity & metabolism.

[7]  T. Nakanishi,et al.  SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria , 2014, Biopharmaceutics & drug disposition.

[8]  J. Rosenstock,et al.  Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes , 2014, Diabetes Care.

[9]  G. Hitman,et al.  LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes , 2014, Diabetes Care.

[10]  S. Engel,et al.  Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta‐analysis , 2014, Diabetes, obesity and metabolism.

[11]  V. Balaji,et al.  A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population , 2014, Indian journal of endocrinology and metabolism.

[12]  M. Monami,et al.  Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials , 2014, Diabetes, obesity & metabolism.

[13]  N. Hawkins,et al.  Dapagliflozin compared with other oral anti‐diabetes treatments when added to metformin monotherapy: a systematic review and network meta‐analysis , 2014, Diabetes, obesity & metabolism.

[14]  M. Weir,et al.  Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR) , 2014, Current medical research and opinion.

[15]  D. Owens,et al.  Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment , 2014, Diabetes, obesity & metabolism.

[16]  B. Hummer,et al.  Pancreatic safety of incretin-based drugs--FDA and EMA assessment. , 2014, The New England journal of medicine.

[17]  P. Nyirjesy,et al.  Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies , 2014, Current medical research and opinion.

[18]  Chun-Yuh Yang,et al.  Pioglitazone use and the risk of bladder cancer , 2014, The Kaohsiung journal of medical sciences.

[19]  J. Rosenstock,et al.  Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia , 2013, Diabetes, obesity & metabolism.

[20]  J. Rosenstock,et al.  Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515 , 2013, Diabetes Care.

[21]  M. Roden,et al.  Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2013, The lancet. Diabetes & endocrinology.

[22]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[23]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[24]  Lawrence A Leiter,et al.  Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial , 2013, The Lancet.

[25]  K. Johnsson,et al.  Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. , 2013, Journal of diabetes and its complications.

[26]  D. Matthews,et al.  Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes , 2013, Annals of Internal Medicine.

[27]  K. Mahaffey,et al.  Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. , 2013, American heart journal.

[28]  D. Nathan,et al.  Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) , 2013, Diabetes Care.

[29]  W. White,et al.  Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus , 2013, Diabetes, obesity & metabolism.

[30]  K. Kim,et al.  Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise , 2013, Diabetes, obesity & metabolism.

[31]  S. Inzucchi,et al.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 , 2013, Diabetes Care.

[32]  A. Barnett,et al.  Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature , 2012, Diabetes, obesity & metabolism.

[33]  Thomas M. MacDonald,et al.  Pioglitazone and bladder cancer: a propensity score matched cohort study. , 2013, British journal of clinical pharmacology.

[34]  S. Inzucchi,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[35]  P. Donnan,et al.  Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs , 2012, Diabetologia.

[36]  G. Musso,et al.  A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials , 2012, Annals of medicine.

[37]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[38]  E. Ferrannini,et al.  SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects , 2012, Nature Reviews Endocrinology.

[39]  E. Bosi,et al.  Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52‐week, randomized, double‐blind, active‐controlled, parallel‐group study , 2011, Diabetes, obesity & metabolism.

[40]  S. Del Prato,et al.  Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin , 2011, Diabetes Care.

[41]  S. Mudaliar,et al.  Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[42]  K. Lipska,et al.  Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency , 2011, Diabetes Care.

[43]  P. Raskin,et al.  A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[44]  I. Hirsch,et al.  Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials , 2011, Annals of Internal Medicine.

[45]  W. Herrington,et al.  Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease? , 2011, Nephron Clinical Practice.

[46]  M. S. Lewis,et al.  Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes , 2011, Annals of Internal Medicine.

[47]  H. Pilmore.  Review: Metformin: Potential benefits and use in chronic kidney disease , 2010, Nephrology.

[48]  R. DeFronzo,et al.  Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). , 2010, The Journal of clinical endocrinology and metabolism.

[49]  C. O'connor,et al.  Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes , 2010, Diabetes Care.

[50]  Michael E. Miller,et al.  ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .

[51]  E. Wright,et al.  Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. , 2009, Kidney international.

[52]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[53]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[54]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[55]  A. Farmer,et al.  Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. , 2007, The New England journal of medicine.

[56]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[57]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.

[58]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[59]  M. Laakso,et al.  The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data , 1998, Diabetes Care.

[60]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[61]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[62]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.